Written by: Jeff Engle, PharmD, MS
Download Here

This PQI will discuss effective management of adverse effects of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma and discuss data supporting the sequencing of patients to second-line therapy with regorafenib for increased survival benefit.

Continue reading Sorafenib for the Treatment of Hepatocellular Carcinoma and Transition to Second-line Regorafenib

Read More